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Early observations suggested that the inhibition by long-acting ,&agonists (LABAs) of non-specific bronchial 
hyperresponsiveness following allergen challenge was unrelated to bronchodilation or functional antagonism and 
might be a reflection of anti-inflammatory activity. 
Investigation of the effect of LABAs on airway inflammatory responses has demonstrated an inhibition of 
eosinophil recruitment in allergen challenge studies. Nevertheless, results from biopsy and other studies suggest that 
the chronic inflammatory process in asthma patients is unaffected by these drugs. There is no evidence from biopsy 
studies that LABAs are pro-inflammatory or that they mask existing inflammation. 
The beneficial effects of LABAs in allergen challenge are probably mediated through stabilization of mast cells. 
Recent evidence suggests that LABAs may reduce numbers of neutrophils and their associated markers; this 
observation needs to be confirmed in future studies and its relevance to the treatment of asthma determined. 
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Introduction 
The introduction in the 1990s of the long-acting Pz-agonists 
(LABAs) salmeterol and formoterol provided asthma 
patients with an effective way of controlling asthma 
symptoms, particularly nocturnal asthma. However, studies 
in asthmatic patients suggest that as well as producing 
bronchodilatation, a LABA can directly modulate bron- 
chial hyperreactivity induced by allergen (1,2) or by 
adenosine monophosphate (AMP) (3). This finding was 
not adequately explained by the bronchodilator or func- 
tional antagonist properties of these drugs, and suggested 
that they might have anti-inflammatory properties. Results 
from in vivo and in vitro studies in experimental animals 
(4,s) and in vitro studies on human lung (6) appeared to 
support this hypothesis. 
In a bronchoalveolar lavage (BAL) study in the early 
1990s twice daily treatment with salmeterol 50,~g for 
4 weeks in patients with mild asthma produced an 
improvement in the macroscopic appearance of the 
bronchial mucosa during bronchoscopy and a significant 
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reduction in eosinophil cationic protein (ECP) levels in 
BAL fluid, accompanied by a clinical improvement (7). 
However, subsequent clinical studies have produced con- 
trasting results, as described in this review. 
Effects of LABAs on eosinophils and 
lymphocytes 
In allergen challenge studies, LABAs have been shown to 
reduce the number of eosinophils. However, studies in 
patients with chronic asthma published in the last 3 years 
have not shown any reductions in inflammatory cells after 
salmeterol treatment, presenting an interesting contrast to 
the work done in the allergen challenge setting. Although 
some reports have suggested that LABAs may aggravate 
inflammation or mask a deterioration in asthma pathology 
(8,9), no evidence was found of increases in cell numbers or 
levels of inflammatory markers in any of the studies 
reviewed below, in which LABAs were given as mono- 
therapy. 
ALLERGEN CHALLENGE STUDIES 
In an early allergen challenge study, Dahl’s group reported 
that a single dose of salmeterol 50 or lOO/*g inhibited the 
early and late asthmatic responses in asthmatic patients 
after allergen challenge; although salmeterol inhibited the 
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post-challenge increase in serum ECP, it had no effect on 
the accompanying rise in eosinophil numbers (10). Subse- 
quently, inhibition of eosinophil recruitment by salmeterol 
has been shown in two studies. In the first, patients with 
atopic asthma receiving salmeterol 50,~g twice daily for 
7 days were challenged with allergen on day 5; eosinophil 
numbers in BAL fluid were significantly reduced 48 h after 
challenge (11). In the second, a single dose of salmeterol 
50 pg inhibited the increase in sputum eosinophils 24 h after 
allergen challenge (12). In a comparative study in patients 
with mild asthma, two doses of salmeterol 50 pg in 24 h 
significantly reduced post-challenge BAL levels of ECP, 
interleukin (IL)-4 and IL-5 compared with placebo 
but did not reduce eosinophil recruitment (13). In a recent 
cross-over study investigating the response to allergen 
challenge in 13 patients with mild asthma before and after 
treatment with salmeterol 50 pug twice daily for 6 weeks, 
analysis of biopsy samples showed significant reductions in 
the total number of leucocytes (median reduction: 44%) 
and the number of plasma cells (81%) compared with 
baseline (14). 
In a pilot study in mild asthmatics, 8 weeks of treatment 
with salmeterol 50,~g twice daily produced greater reduc- 
tions than placebo in the recruitment of lymphocyte sub- 
populations and mast cells after allergen challenge (15). 
However, no anti-inflammatory effect was found in a 
subsequent study by the same group in which the same 
dosage of salmeterol was given for only 1 week before 
allergen challenge; indeed, mast cell numbers in the 
salmeterol group were nearly twice as high as in patients 
on placebo (16). 
STUDIES IN CHRONIC ASTHMA 
Eosinophil recruitment in BAL from 10 asthmatic patients 
was unaffected by treatment with salmeterol 100,~g twice 
daily for 6 weeks (17). Two other groups who used 
assessments other than bronchial biopsy failed to demon- 
strate any anti-inflammatory properties of salmeterol 50 pg 
given twice daily. In the first study, treatment with 
salmeterol for 1 week with or without budesonide 8OOpg 
had no effect on exhaled nitric oxide levels in patients with 
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mild asthma (18); the second study, in chronic asthmatics 
with mild asthma exacerbations (increased symptoms for at 
least 2 weeks), showed no significant reduction in sputum 
eosinophil numbers after 3 weeks of treatment with 
salmeterol 5Opg twice daily compared with placebo (19). 
These findings have been confirmed by more recent work 
involving immunohistochemical analysis of cell markers 
from bronchial biopsy as well as BAL; in this study, 
salmeterol given 50 pg twice daily for 6 weeks had no effect 
on inflammatory cell numbers (Fig. 1) or function, collagen 
deposition in the basement membrane (BM) or levels of 
inflammatory mediators in mild atopic patients (20). In 
patients with mild asthma treated with formoterol 24pg 
twice daily for 8 weeks, a significant reduction in EG2+ 
eosinophils was apparent, although this was only seen in a 
subgroup of patients whose inflammation at baseline was 
more severe (21). 
Effects on neutrophils and mast cells 
In addition to the reported inhibitory effect of salmeterol 
on mast cell proliferation after allergen challenge (15), 
significant reduction of mast cell numbers was produced by 
twice daily treatment with formotero124 pg for 8 weeks in a 
group of mild asthmatic patients (21). 
It has been established that neutrophils make an 
important contribution to the inflammatory process in 
COPD patients through the release of defensins and serine 
proteases such as elastase and cathepsin G, all of which 
reduce epithelial integrity and stimulate mucus production 
(22); however, the neutrophil’s role in asthma is less well 
characterized. Although the numbers of neutrophils in 
biopsies from patients with severe asthma are approxi- 
mately twice those in patients with moderate asthma (23), 
this may be attributable to oral corticosteroid treatment 
rather than to a difference in pathology. Numbers of 
neutrophils have been shown to be raised at night in 
patients with nocturnal asthma (24). There is some evidence 
from in vitro studies that LABAs can inhibit the activation 
or function of neutrophils, possibly through P-receptor- 
independent mechanisms (25-27), but data from clinical 
studies are inconclusive. Although salmeterol had no 
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FIG. 1. Median numbers of (a) mast cells and (b) eosinophils in biopsy samples taken from patients with mild atopic asthma, 
before ( n ) and after ( q ) twice daily treatment with salmeterol 50 pg (n = 14) or placebo (n = 12) for 6 weeks. [Reproduced 
from Roberts et al. (1999) permission not required (20).] 
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significant effects on neutrophil numbers in BAL in two 
studies in patients with mild asthma (17,20), results from a 
recent cross-over study showed that treatment with 
salmeterol 50,~g for 6 weeks significantly reduced biopsy 
neutrophil numbers compared with placebo in patients with 
mild, stable asthma (28). These findings are supported by 
the results of another recent study in 45 patients receiving 
ICS treatment (median dose: 400,~gday-’ of beclometha- 
sone dipropionate or equivalent) for mild-to-moderate 
asthma. The addition of salmeterol 5Opg twice daily for 3 
months to the patients’ ICS therapy significantly reduced 
levels of IL-8 (a potent neutrophil chemoattractant) in BAL 
fluid compared with baseline and there was also a trend 
towards reduced neutrophil numbers in BAL fluid (29). 
Mode of action 
Two possible explanations can be offered for the contrast- 
ing properties of LABAs in clinical studies of allergen 
challenge and chronic asthma. First, they may arise from 
differences in the cellular mechanisms involved. Whereas 
chronic asthma is characterized by lymphocyte and 
eosinophil activation, the acute inflammatory response seen 
after allergen challenge is also dependent on the IgE- 
mediated release of histamine, prostaglandins and tumour 
necrosis factor-alpha from mast cells, which can be 
inhibited by LABAs (30,31). Neutrophils may also be 
important in the acute inflammatory response (32,33). 
A second explanation may be the inter-patient variability 
in &receptor responsiveness. Most allergen challenge 
studies are conducted in atopic patients with extremely 
mild disease. As the &-receptor responsiveness of these 
patients is greater than in patients with chronic stable 
asthma, who develop tolerance to ,02-agonists given 
chronically, mast cell activation in allergen challenge 
patients may be more susceptible to inhibition by a & 
agonist. In this respect, it is interesting that the severity of 
asthma in the patients in the study by Wallin et al. (21) was 
less than that of the patients in the other chronic asthma 
studies reviewed in this paper, and similar to the asthma 
severity in the patients enrolled in the allergen challenge 
studies. 
Conclusions 
From the results of the studies reviewed, it is difficult to 
conclude that LABAs have any consistent beneficial effect 
on a particular inflammatory pathway in chronic asthma. 
The mast-cell-inhibiting property of P-agonists may explain 
the ability of LABAs to modify the LAR in allergen 
challenge studies. On the other hand, these data provide 
direct evidence that LABAs have no significant pro- 
inflammatory effect, suggesting that LABAs do not mask 
or aggravate underlying inflammation in asthma patients. 
In addition to an inhibitory effect on mast cells, LABAs 
may cause a reduction in the number and activation of 
neutrophils, but the relevance of these effects for the long- 
term control of airway inflammation has yet to be 
established. 
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